Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of Angiomax as an
anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced
thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass
(OPCAB) surgery.